PLUR

Pluri Inc. (PLUR) | Rumor.io

Pluri

PLUR

Attention (50-day avg)0%

Attention rank (50-day avg)#4,294

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization12M

Earnings per share-2.42

Dividend yield (TTM)—

Revenue (annual)1M

Net income (annual)-25.4M

Social

What share of all stock conversation is about PLUR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Apr 24

$PLUR is identified as a potential hedge against nuclear exposure with Ukraine news, due to its patents and recent price jump from 3 to 7.
The company's share price has been poor but has recently increased from 3 to almost 7 in a few days.
The author is seeking thoughts and opinions from followers about the company, with limited discussion currently present.

Generated by AI

Sentiment

Of the messages about PLUR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	98.87% +23.43
Bearish	—	—	—	1.13% -23.43

Bullish· Jan 10

$PLUR has a strong support level at $1.70, making it a solid investment opportunity.
The company's sales model, which combines resale of third-party products and high-margin recurring revenue products, has been highlighted by a Leede Jones Gable analyst as a key factor in their "Buy" rating.
$PLUR is poised for a significant price increase, with some analysts predicting a 40% gain, and traders are looking for a clean break and hold over $1.82 to trigger a run.

Bearish· Jan 10

*PLUR has seen significant share unloading, with the bid being down all day, suggesting a potential sell-off.
*The company's price action is looking "horrendous" and the 15-minute close candle is "ugly", indicating a bearish trend.
*The stock's market cap is smaller than the net loss, suggesting a potential scam or pump and dump, and the high volume traded is not translating to a higher stock price.

Generated by AI

Topics

Of the messages about PLUR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	0.28%
Analysts	—	—	—	2.1%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	97.47%
Technical Analysis	—	—	—	0.16%

Jan 10

Pluristem Therapeutics has formed a joint venture with Tnuva Group, Israel's largest food conglomerate, to develop a cultured food platform.
The partnership involves an investment of $7.5 million in NewCo, with an option to invest up to an additional $7.5 million over 12 months, based on a pre-money valuation of $40 million.
The collaboration aims to leverage Pluristem's cell-based technology platform and Tnuva's manufacturing and logistics capabilities to make cultured food products more affordable for consumers.

Generated by AI

Community

Of the messages about PLUR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	0.69%
Newcomers	—	—	—	99.31%

Dec 16

New users are feeling optimistic about Pluri Inc., mentioning its "vibes" and suggesting it for a "more lit move".
Some newcomers are comparing Pluri Inc.'s performance to other companies, such as Tesla and Kohl's, noting a 1.32% decline in Pluri's stock.
Users are observing and commenting on the premarket action of other companies, such as Kohl's, and making jokes about the thin spread.

Generated by AI

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

20d agoYahoo Finance

Pluri Announces August 2026 Equity Financing Transaction

Detailed price information for Pluri Inc (PLUR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Pluri raises $3.3 million in registered direct offering

1mo agoInvesting.com

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

HAIFA, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two principal business verticals: (i) Human Health & Longevity and (ii) FoodTech & Bio-Farming, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor, for the purchase and sale of 2,228,940 Common Shares (or Common Sha

1mo agoYahoo Finance

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presenceEver After Foods secures an additional $2 million strategic investment supporting ongoing platform development and commercialization activities. HAIFA, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across ther

1mo agoYahoo Finance

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

UK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a market with an estimated size of ~$900 million annually, and strengthens the foundation for broader international expansion HAIFA, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announc

2mo agoYahoo Finance

Also Discussed

Investors talking about PLUR also mention

#	Name	Attention
1	Mesoblast Ltd Sponsored ADRMESO	0%0
2	The Nightview FundNITE	0%0
3	Collplant Biotechnologies LtdCLGN	0%0
4	Independent Bank CorporationIBCP	0%new
5	Pamt CorpPTSI	0%0
6	CYAD - Celyad Oncology S.A.	——
7	Global X Genomics & Biotechnology ETFGNOM	0.01%+0
8	ENZ - Enzo Biochem, Inc.	——
9	Protalix BioTherapeutics, Inc.PLX	0%+0
10	Compugen LtdCGEN	0%new

Pluri Inc.

Healthcare
Biotechnology

Pluri Inc. is a biotechnology company focused on the research, development, manufacturing, and commercialization of cell-based products and related technologies. The company uses its proprietary three-dimensional cell expansion platform to support scalable cell production for applications across regenerative medicine, immunotherapy, food technology, and agricultural technology. Its current business areas include cell therapeutics, cultivated food solutions, and contract development and manufacturing services, reflecting a diversified platform built around advanced cell engineering. Pluri Inc. serves markets that rely on biological innovation to address medical, industrial, and sustainability challenges, positioning itself as a provider of cell-based solutions for both therapeutic and non-therapeutic uses. Headquartered in Haifa, Israel, Pluri Inc. operates as a clinical-stage biotechnology company with a focus on translating cell technology into practical commercial products and services.

Website

Location

MATAM Advanced Technology Park

Haifa, 3508409

Israel

Social

What share of all stock conversation is about PLUR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Apr 24

$PLUR is identified as a potential hedge against nuclear exposure with Ukraine news, due to its patents and recent price jump from 3 to 7.
The company's share price has been poor but has recently increased from 3 to almost 7 in a few days.
The author is seeking thoughts and opinions from followers about the company, with limited discussion currently present.

Generated by AI

Sentiment

Of the messages about PLUR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	98.87% +23.43
Bearish	—	—	—	1.13% -23.43

Bullish· Jan 10

$PLUR has a strong support level at $1.70, making it a solid investment opportunity.
The company's sales model, which combines resale of third-party products and high-margin recurring revenue products, has been highlighted by a Leede Jones Gable analyst as a key factor in their "Buy" rating.
$PLUR is poised for a significant price increase, with some analysts predicting a 40% gain, and traders are looking for a clean break and hold over $1.82 to trigger a run.

Bearish· Jan 10

*PLUR has seen significant share unloading, with the bid being down all day, suggesting a potential sell-off.
*The company's price action is looking "horrendous" and the 15-minute close candle is "ugly", indicating a bearish trend.
*The stock's market cap is smaller than the net loss, suggesting a potential scam or pump and dump, and the high volume traded is not translating to a higher stock price.

Generated by AI

Topics

Of the messages about PLUR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	0.28%
Analysts	—	—	—	2.1%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	97.47%
Technical Analysis	—	—	—	0.16%

Jan 10

Pluristem Therapeutics has formed a joint venture with Tnuva Group, Israel's largest food conglomerate, to develop a cultured food platform.
The partnership involves an investment of $7.5 million in NewCo, with an option to invest up to an additional $7.5 million over 12 months, based on a pre-money valuation of $40 million.
The collaboration aims to leverage Pluristem's cell-based technology platform and Tnuva's manufacturing and logistics capabilities to make cultured food products more affordable for consumers.

Generated by AI

Community

Of the messages about PLUR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	0.69%
Newcomers	—	—	—	99.31%

Dec 16

New users are feeling optimistic about Pluri Inc., mentioning its "vibes" and suggesting it for a "more lit move".
Some newcomers are comparing Pluri Inc.'s performance to other companies, such as Tesla and Kohl's, noting a 1.32% decline in Pluri's stock.
Users are observing and commenting on the premarket action of other companies, such as Kohl's, and making jokes about the thin spread.

Generated by AI

Pluri

Social

Apr 24

Sentiment

Bullish· Jan 10

Bearish· Jan 10

Topics

Jan 10

Community

Dec 16

News

Pluri: Fiscal Q4 Earnings Snapshot

Pluri Announces August 2026 Equity Financing Transaction

Pluri raises $3.3 million in registered direct offering

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

Also Discussed

Pluri Inc.

Company Information

Location

News

Pluri: Fiscal Q4 Earnings Snapshot

Pluri Announces August 2026 Equity Financing Transaction

Pluri raises $3.3 million in registered direct offering

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

Also Discussed

Social

Apr 24

Sentiment

Bullish· Jan 10

Bearish· Jan 10

Topics

Jan 10

Community

Dec 16